Professor ChunRong Ju’s Comments: Focus on Long-Term Infections in Solid Organ Transplant Recipients | ESCMID Global 2024

Professor ChunRong Ju’s Comments: Focus on Long-Term Infections in Solid Organ Transplant Recipients | ESCMID Global 2024

2024.05.09
Infection remains a major challenge for recipients of solid organ transplants (SOT), leading to serious risks of mortality and transplant failure. Previous research has primarily focused on the characteristics and prevention of infections within the first year post-surgery, with limited data on long-term infections beyond one year post-surgery. At the recent 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2024 Annual Meeting, a large-scale follow-up study from Switzerland reported that SOT recipients still face a high incidence of infections and disease burden beyond one year post-surgery.
Optimizing Antibiotic Dosage in Obese and Underweight Patients: Insights from Professor Wenxiang Huang ‘s Presentation at ESCMID Global 2024

Optimizing Antibiotic Dosage in Obese and Underweight Patients: Insights from Professor Wenxiang Huang ‘s Presentation at ESCMID Global 2024

2024.05.09
From April 27th to 30th, 2024, the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024) took place in Barcelona, Spain, known as the "Pearl of the Iberian Peninsula." ESCMID Global, formerly known as ECCMID, stands as one of the most influential international conferences in the field of infectious diseases. Often, clinical trials of antibiotics exclude special populations such as obese or underweight individuals, resulting in limited evidence for their treatment strategies. At this conference, several studies and advancements regarding antibiotic management and prescription, including interventions, monitoring, influences, decision support/predictive tools, and behavioral aspects, were reported. Below is a summary of the insights shared by Professor Wenxiang Huang from the Department of Geriatrics at The First Affiliated Hospital of Chongqing Medical University.
 Professor Tiejun Gong: Striving for Excellence, 2024 CSCO Guidelines on Malignant Hematology with a Focus on Leukemia | 2024 CSCO Guidelines Conference

 Professor Tiejun Gong: Striving for Excellence, 2024 CSCO Guidelines on Malignant Hematology with a Focus on Leukemia | 2024 CSCO Guidelines Conference

2024.05.08
The 2024 China Clinical Oncology Society (CSCO) Guidelines Conference was held in Jinan on April 26-27, 2024. As always, the conference updated and released multiple CSCO cancer treatment guidelines. Professor Tiejun Gong, Deputy Director of the Harbin Institute of Hematologic Oncology, gave an insightful interpretation of the leukemia section in the "2024 CSCO Guidelines on Malignant Hematology." After the conference, "Oncology Frontier - Hematology Frontier" invited Professor Gong to introduce the characteristics and updates in leukemia treatment in the 2024 CSCO Malignant Hematology Guidelines, discuss current challenges in leukemia treatment, and express his views on potential improvements.
EBMT 2024 | Dr. Li Gao：The MRD status on day 7 and CD4 count at 1 month after CAR-T therapy are prognostic indicators in CAR-T treatments

EBMT 2024 | Dr. Li Gao：The MRD status on day 7 and CD4 count at 1 month after CAR-T therapy are prognostic indicators in CAR-T treatments

2024.05.08
From April 14 to 17, 2024, the 50th Annual Congress of the European Society for Blood and Marrow Transplantation (EBMT) was held with great ceremony in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, advancing patients with hematological diseases towards better clinical prognoses. At this congress, Dr. Li Gao from Soochow University Affiliated Children's Hospital reported on a study.
2024 CUDA Yanqi Lake Conference | Professor Xuesong Li: Optimizing Prostate Cancer Management to Safeguard Men’s Lives

2024 CUDA Yanqi Lake Conference | Professor Xuesong Li: Optimizing Prostate Cancer Management to Safeguard Men’s Lives

2024.05.08
The "4th Chinese Medical Association Urology Surgeons Branch Yanqi Lake Conference (2024)" was successfully held in Beijing from April 13th to 14th. The conference not only focused on clinical practices in urology surgery but also discussed cutting-edge developments and important topics in the industry. At the conference, Professor Xuesong Li from Peking University First Hospital shared insights on "Optimizing Prostate Cancer Management to Safeguard Men's Lives." "Oncology Frontier - Urology News" has specially compiled relevant content for readers.
2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis

2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis

2024.05.08
With the development of targeted therapy and immunotherapy, the treatment options for malignant hematologic diseases continue to expand. The "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Malignant Hematologic Diseases (2024)" has once again been updated. "Oncology Watch" specially interviewed one of the guideline's authors, Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology, to provide in-depth explanations on the highlights of the guideline updates, their impact on clinical practice, and the implementation of the guidelines.
Professor Qing Cao’s Commentary: Emerging Staphylococcus Threatens Newborn Health | ESCMID Global 2024

Professor Qing Cao’s Commentary: Emerging Staphylococcus Threatens Newborn Health | ESCMID Global 2024

2024.05.08
In low- and middle-income countries, the health of newborns faces numerous challenges, with neonatal sepsis being a particularly grave concern. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study (abstract number: O0158) focused on the threat posed by Coagulase-Negative Staphylococci (CoNS) to newborn health. These bacteria, increasingly reported in low- and middle-income countries, exhibit insensitivity to multiple commonly used antibiotics, complicating treatment. Professor Qing Cao from the Shanghai Children's Medical Center, affiliated with Shanghai Jiao Tong University School of Medicine, provides a detailed commentary on this study, sharing her professional insights and recommendations.
EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

2024.05.08
Induction therapies with high remission rates, combined with high-dose chemotherapy and autologous stem cell transplantation (ASCT), have significantly improved the prognosis for multiple myeloma (MM) patients. Despite this, patients still inevitably experience disease progression or relapse. One of the key goals in this research field is how to maintain remission in patients after induction therapy and ASCT. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with hematological diseases and cancers. At this conference, Professor Jean-Luc Harousseau, Chairman of the French National Health Authority and Director of the René Gauducheau Cancer Center at the University of Nantes, delivered an insightful presentation on optimizing induction therapy strategies for multiple myeloma patients before ASCT. "Hematology Frontier" invited Professor Harousseau to share his insights on continuously optimizing pre-ASCT induction therapy for multiple myeloma patients.